Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EPS (Basic) (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EPS (Basic) for 16 consecutive years, with -$1.24 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 217.95% to -$1.24 in Q4 2025 year-over-year; TTM through Oct 2025 was -$0.79, a 241.07% decrease, with the full-year FY2025 number at $3.19, up 277.22% from a year prior.
  • EPS (Basic) was -$1.24 for Q4 2025 at PharmaCyte Biotech, down from -$1.23 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $2.12 in Q2 2025 to a low of -$1.24 in Q4 2025.
  • A 5-year average of -$0.16 and a median of -$0.31 in 2023 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): crashed 71806.73% in 2021, then skyrocketed 778.57% in 2024.
  • PharmaCyte Biotech's EPS (Basic) stood at -$0.06 in 2021, then plummeted by 50.0% to -$0.09 in 2022, then tumbled by 533.33% to -$0.57 in 2023, then surged by 31.58% to -$0.39 in 2024, then crashed by 217.95% to -$1.24 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's EPS (Basic) are -$1.24 (Q4 2025), -$1.23 (Q3 2025), and $2.12 (Q2 2025).